巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    PaxMedica

    PXMD
    2.420
    0.100
    3.97%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・PaxMedica - 延遲價格・最後更新於 29/09 8:28
    最高位
    2.480
    最低位
    2.270
    開市價
    --
    前收市價
    2.520
    成交量(千)
    1.96
    成交額(百萬)
    0.05
    買入
    2.000
    賣出
    2.910
    每手股數
    --
    市值(百萬)
    0.00
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    10.480 - 2.040
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    PaxMedica
    證券代碼
    PXMD.US
    所屬板塊
    Biotechnology
    公司業務
    PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
    發行量
    0
    公司總部
    50 Tice Boulevard, Suite A26
    公司網址
    https://www.paxmedica.com
    公司電郵
    info@paxmedica.com
    公司電話
    +1 201 645-4765
    暫無內容

    關於

    PaxMedica(PXMD.US)所屬的行業板塊為Biotechnology。
    PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
    詳細公司背景可參考: https://www.paxmedica.com